The Effects of Ex Vivo Administration of Granulocyte-Macrophage Colony-Stimulating Factor and Endotoxin on Cytokine Release of Whole Blood Are Determined by Priming Conditions

Background Lipopolysaccharide- (LPS-) induced tumour necrosis factor alpha (TNFα) secretion in critically ill patients can be considered as a measure of immune responsiveness. It can be enhanced by granulocyte-macrophage colony stimulating factor (GM-CSF). We investigated the effect of GM-CSF on ex vivo stimulated cytokine production using various preincubation regimens in healthy donors and patients with sepsis. Results The maxima for the stimuli occurred 3 hours after stimulation. In donors, there was an increase (p < 0.001) of LPS-induced TNFα levels following incubation with GM-CSF. The simultaneous incubation with GM-CSF and LPS caused an inhibition of TNFα production (p < 0.001). Postincubation with GM-CSF did not yield any difference. In patients, preincubation with GM-CSF yielded an enhanced ex vivo TNFα-response when TNFα levels were low. Patients with increased TNFα concentrations did not show a GM-CSF stimulation effect. The GM-CSF preincubation yielded an increase of IL-8 production in patients and donors. Conclusions This study demonstrates the immune-modulating properties of GM-CSF depending on the absence or presence of LPS or systemic TNFα. The timing of GM-CSF administration may be relevant for the modulation of the immune system in sepsis. The lack of stimulation in patients with high TNFα may represent endotoxin tolerance.

[1]  J. Kellum,et al.  Immune Cell Phenotype and Function in Sepsis , 2016, Shock.

[2]  M. Netea,et al.  Defective cytokine production early after multiple traumas: Modulation in severe sepsis. , 2015, Cytokine.

[3]  WrightCraig Robert,et al.  Regulation of Granulocyte Colony-Stimulating Factor and Its Receptor in Skeletal Muscle Is Dependent Upon the Type of Inflammatory Stimulus , 2015 .

[4]  P. Pickkers,et al.  Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. , 2015, Minerva anestesiologica.

[5]  R. Hotchkiss,et al.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy , 2013, Nature Reviews Immunology.

[6]  J. Hamilton,et al.  Colony stimulating factors and myeloid cell biology in health and disease. , 2013, Trends in immunology.

[7]  L. Koenderman,et al.  Immunotherapy after trauma: timing is essential , 2011, Current opinion in anaesthesiology.

[8]  J. Estaquier,et al.  Cytokines modulate neutrophil death. , 2010, European cytokine network.

[9]  T. Baumann,et al.  Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. , 2009, American journal of respiratory and critical care medicine.

[10]  T. Baumann,et al.  blind randomized placebo-controlled multicenter trial , 2009 .

[11]  G. Franklin,et al.  Systemic inflammation after trauma. , 2007, Injury.

[12]  A. Ayala,et al.  Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock , 2007, Critical care medicine.

[13]  M. Hino,et al.  Selective activation of STAT3 in human monocytes stimulated by G-CSF: implication in inhibition of LPS-induced TNF-alpha production. , 2004, American journal of physiology. Cell physiology.

[14]  T. Hartung,et al.  Perioperative Recombinant Human Granulocyte Colony-Stimulating Factor (Filgrastim) Treatment Prevents Immunoinflammatory Dysfunction Associated With Major Surgery , 2004, Annals of surgery.

[15]  S. Lendemans,et al.  Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma , 2003, Critical care medicine.

[16]  G. Otto,et al.  GM-CSF Restores Innate, But Not Adaptive, Immune Responses in Glucocorticoid-Immunosuppressed Human Blood In Vitro1 , 2003, The Journal of Immunology.

[17]  A. Nierhaus,et al.  Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis , 2003, Intensive Care Medicine.

[18]  P. Newburger,et al.  Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. , 2002, Blood.

[19]  John W. Wilson,et al.  A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. , 2002, American journal of respiratory and critical care medicine.

[20]  J. Marshall,et al.  Measurement of endotoxin activity in critically ill patients using whole blood neutrophil dependent chemiluminescence , 2002, Critical care.

[21]  O. Derman,et al.  A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. , 2001, Pediatrics.

[22]  T. Hartung,et al.  Blood cytokine response of low-dose molgramostim (rhGM-CSF)-treated patients. , 2000, Cytokine.

[23]  J. Klein,et al.  Granulocyte-Macrophage Colony-Stimulating Factor Delays Neutrophil Constitutive Apoptosis Through Phosphoinositide 3-Kinase and Extracellular Signal-Regulated Kinase Pathways1 , 2000, The Journal of Immunology.

[24]  H. Volk,et al.  Clinical aspects: from systemic inflammation to 'immunoparalysis'. , 2000, Chemical immunology.

[25]  E. Kreuzfelder,et al.  HLA-DR expression and soluble HLA-DR levels in septic patients after trauma. , 1999, Annals of surgery.

[26]  M. Williams,et al.  Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. , 1998, The Journal of infectious diseases.

[27]  J. Cavaillon,et al.  Reduced ex vivo interleukin-8 production by neutrophils in septic and nonseptic systemic inflammatory response syndrome. , 1998, Blood.

[28]  N. Petrelli,et al.  Randomized, placebo-controlled, multicenter trial of granulocyte-macrophage colony-stimulating factor as infection prophylaxis in oncologic surgery. Leukine Surgical Prophylaxis Research Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Williams,et al.  Granulocyte-macrophage colony-stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients. , 1998, The Journal of infectious diseases.

[30]  F. Schade,et al.  Regulation of whole blood tumor necrosis factor production upon endotoxin stimulation after severe blunt trauma. , 1997, The Journal of trauma.

[31]  T. Hartung,et al.  Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. , 1997, Blood.

[32]  T. van der Poll,et al.  Changes in endotoxin-induced cytokine production by whole blood after in vivo exposure of normal humans to endotoxin. , 1996, The Journal of infectious diseases.

[33]  R. Bone,et al.  Sir Isaac Newton, sepsis, SIRS, and CARS. , 1996, Critical care medicine.

[34]  L. V. Van Pelt,et al.  A single dose of granulocyte-macrophage colony-stimulating factor induces systemic interleukin-8 release and neutrophil activation in healthy volunteers. , 1996, Blood.

[35]  K. Asadullah,et al.  Very low monocytic HLA-DR expression indicates high risk of infection--immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. , 1995, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[36]  Marc A. Williams,et al.  Administration of rHuGM‐CSF activates monocyte reactive oxygen species secretion and adhesion molecule expression in vivo in patients following high‐dose chemotherapy , 1995, British journal of haematology.

[37]  F. Schildberg,et al.  Downregulation of proinflammatory cytokine release in whole blood from septic patients. , 1995, Blood.

[38]  W. Hiddemann,et al.  Endotoxin concentration in neutropenic patients with suspected gram-negative sepsis: correlation with clinical outcome and determination of anti-endotoxin core antibodies during therapy with polyclonal immunoglobulin M-enriched immunoglobulins , 1992, Antimicrobial Agents and Chemotherapy.

[39]  J. Cavaillon,et al.  Dysregulation of in vitro cytokine production by monocytes during sepsis. , 1991, The Journal of clinical investigation.

[40]  H. Polk,et al.  HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. , 1991, American journal of surgery.

[41]  H. Polk,et al.  Monocyte HLA‐DR antigen expression characterizes clinical outcome in the trauma patient , 1990, The British journal of surgery.

[42]  D. Metcalf.  The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. , 1986, Blood.